Drug Discovery
By
Can Catalio Capital’s $400 Million AI-Driven Life Sciences Fund Ignite a New Era of Biomedical Innovation Despite a Slow VC Market?
Key Takeaways Resilience in a Cooling VC ClimateCatalio Capital Management has successfully closed its fourth Nexus Fund at…
Is Portal Biotech’s $35M Series A Set to Redefine Proteomics With the World’s First AI-Powered Full-Length Single-Molecule Protein Sequencer?
Key Takeaways Transforming Protein Sequencing With AI and Nanopore InnovationPortal Biotech, a London-based pioneer in proteomics, is aiming…
How Is XtalPi’s Expanded Collaboration With Pfizer Set to Transform AI-Driven Small Molecule Drug Discovery?
Key Takeaways Empowering Next-Gen AI Platforms for Predictive Drug DiscoveryXtalPi and Pfizer have extended their strategic partnership to…
Is AI-Engineered HMBD-002 the Next Big Immunotherapy? Hummingbird Bioscience Signs $290M Global Licensing Deal with Percheron Therapeutics
Key Highlights Strategic Global Licensing Deal Hummingbird Bioscience has signed a worldwide licensing agreement with Percheron Therapeutics for…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R Inhibition, Revolutionize Treatment for Sjögren’s Disease?
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug Price Cuts Signal a New Era of Affordable Innovation and Domestic Manufacturing?
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
